Peptide Initiative

Dosing protocol · Growth Hormone

Sermorelin dosing & administration

The original growth hormone booster that works with your body's natural rhythm—it tells your pituitary gland to release more GH instead of replacing it, keeping your hormonal feedback system healthy and balanced.

Suggested dose

100 – 300 mcg

Once daily at bedtimeFrequency
SubcutaneousRoute
12+ weeksCycle length

Dosing

How much Sermorelin do I take?

Subcutaneous

Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.

Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.

2 documented dose levels — separate regimens, not a titration schedule

  • 100-200 mcg

    Frequency
    Once daily at bedtime
    Duration
    4-6 weeks

    Community-practice dose, not one studied in adults. The adult trials used 0.5–1 mg twice daily or 2 mg nightly ; the pediatric label dose was 30 mcg/kg at bedtime .

  • 200-300 mcg

    Frequency
    Once daily at bedtime
    Duration
    3-6 months

    Community-practice dose. Twice-daily 1 mg (not 200–300 mcg) is the dose that restored GH and IGF-1 in older men .

Timing

Best time to take

Bedtime injection (30-60 minutes before sleep) is ideal because it amplifies your body's natural nighttime GH pulse. [6][10] Some protocols add a morning dose on waking for enhanced effects. [1][3]

With food?

Inject on an empty stomach—avoid eating for 2-3 hours before injection. Food, especially carbohydrates, can blunt the GH response by raising insulin levels. Fasting enhances sermorelin's effectiveness.

If stacking

Sermorelin pairs excellently with Ipamorelin or GHRP-2/6 for synergistic GH release—they work through different pathways. [11] If stacking, inject at the same time but at different sites. CJC-1295 (without DAC) can extend the GH pulse duration.

Adjusting your dose

Increase if

  • You've used the starting dose for 4+ weeks with no noticeable effects
  • Your IGF-1 levels haven't risen on follow-up blood work
  • You want to try twice-daily dosing for enhanced results
  • Your healthcare provider recommends based on your labs

Decrease if

  • You experience persistent headaches or dizziness
  • Facial flushing becomes uncomfortable or prolonged
  • You feel jittery, anxious, or have trouble sleeping
  • Injection site reactions are significant

Signs of right dose

  • Improved sleep quality—falling asleep easier, deeper sleep
  • Increased energy and sense of well-being
  • Gradual improvements in body composition over months
  • IGF-1 levels rising into healthy range on blood work

Administration

How do I use Sermorelin?

Reconstitution

What you need

  • Bacteriostatic water (BAC water)—the preservative allows multiple uses
  • Insulin syringes (29-31 gauge) for injection
  • Alcohol swabs for cleaning vial tops and injection sites
  • Your sermorelin powder vial

Injection

Route

Subcutaneous injection (just under the skin)—the standard and most effective method for sermorelin

Best sites

  • Belly fat area (about 2 inches from your belly button)
  • Front or outer thigh (middle section)
  • Back of the upper arm

Storage

Before reconstitution

Keep your sermorelin powder refrigerated at 36-46°F (2-8°C) for up to several months. For longer storage, freeze at -4°F (-20°C) or colder. Store in the original sealed vial away from light. Properly stored powder remains stable for 1-2 years.

After reconstitution

Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution—freezing destroys the peptide. Keep away from light and use within 14-28 days for best potency.

Signs of degradation — discard the vial

  • Cloudy or hazy appearance (should be crystal clear)
  • Visible particles or floaters in the solution
  • Color changes—any discoloration means discard it
  • Reduced effectiveness despite proper dosing

Sample daily schedule

  • Bedtime (30-60 minutes before sleep)

    200-300 mcg injection

    Site: Rotate between belly, thigh, and arm

    Primary injection timing (community-practice dose). The adult trials used 1 mg twice daily [1] or 2 mg nightly [3]. Inject on an empty stomach: a glucose load suppressed GHRH-induced GH release. [12]

  • Morning (optional, upon waking)

    100-200 mcg injection

    Site: Different site than evening injection

    Optional second dose for enhanced protocols. Wait at least 30 minutes before eating. Creates an additional GH pulse to complement the nighttime release.

Safety

Is Sermorelin safe?

Side effects

Commonly reported: Injection site reactions, Facial flushing

Less common: Headache, Sleepiness or drowsiness, Nausea, Hyperactivity or difficulty sleeping

Serious side effects

  • Severe allergic reaction

Stop and seek help if

  • Any signs of allergic reaction—stop immediately and seek medical help
  • Persistent headaches that worsen or don't improve after 2 weeks
  • Significant fluid retention or swelling that doesn't resolve
  • Development or worsening of carpal tunnel symptoms
  • Blood sugar control becomes difficult (if diabetic)
  • Your healthcare provider advises discontinuation based on labs or symptoms

Sermorelin should be used under the guidance of a qualified healthcare provider. While it has a strong safety record, it's a prescription peptide that requires proper monitoring. This information is educational—not medical advice. Always consult your doctor before starting, stopping, or changing any hormone therapy.

Flagged pairings

  • Glucocorticoids (prednisone, cortisol) — High-dose steroids can significantly blunt GH response to sermorelin. May reduce effectiveness of therapy.
  • Insulin — GH affects blood sugar. If diabetic, monitor closely and work with your doctor to adjust insulin as needed.
  • Somatostatin analogs (octreotide) — Directly opposes sermorelin's action by blocking GH release. Do not combine—they work against each other.

Published research

What the studies show

  • Moderate human trials (Phase 1-2)
  • Not currently FDA approved. GEREF (sermorelin) was approved in 1997 for growth failure in children with GH deficiency; EMD Serono discontinued it in 2008 and FDA withdrew the approvals at its request in 2009, not for safety or effectiveness reasons. Sermorelin sold today is compounded, not an FDA-approved product.
  1. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men

    Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR · 1992PubMed

    This landmark study showed that twice-daily GHRH (sermorelin) injections in older men completely restored their GH and IGF-1 levels to match those of young men. After just 14 days, the age-related hormone decline was reversed, suggesting that the pituitary gland can still respond—it just needs the right signal.

  2. Endocrine and metabolic effects of long-term administration of GHRH-(1-29)-NH2 in age-advanced men and women

    Khorram O, Laughlin GA, Yen SS · 1997PubMed

    Tested [Nle27]GHRH-(1-29)-NH2, a norleucine analog, not sermorelin itself: 10 mcg/kg nightly for 16 weeks in 9 men and 10 women aged 55-71. GH, IGF-1 and skin thickness rose in both sexes; lean mass, insulin sensitivity, well-being and libido improved in men only; fat, bone density and sleep quality did not change. The only adverse effect was transient hyperlipidemia.

  3. Effects of single nightly injections of GHRH (1-29) in healthy elderly men

    Vittone J, Blackman MR, Busby-Whitehead J, et al. · 1997PubMed

    Six weeks of nightly sermorelin increased nocturnal GH release and improved some measures of muscle strength in healthy elderly men. The study suggested that once-daily dosing helps, but twice-daily dosing may be more effective for maximizing benefits.

  4. In vivo semiquantification of hypothalamic GHRH output in humans: evidence for relative GHRH deficiency in aging

    Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL · 1999PubMed

    This study proved that aging causes reduced GHRH output from the hypothalamus—not just a tired pituitary. The pituitary still responds well to GHRH stimulation in elderly people, which is why sermorelin works: it provides the signal the aging hypothalamus no longer sends strongly enough.

  5. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels

    Sigalos JT, Pastuszak AW, Allison A, Khera M · 2017PubMed

    Men taking sermorelin combined with GHRPs three times daily showed significant increases in IGF-1 levels (from 160 to 239 ng/mL on average). The study confirmed that growth hormone secretagogues are effective for raising IGF-1 in adults seeking to improve body composition.

  6. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

    Prakash A, Goa KL · 1999PubMed

    Sermorelin is the shortest synthetic fragment of growth hormone-releasing hormone that retains full biological activity. A single intravenous 1 mcg/kg dose is a rapid, relatively specific provocative test for growth hormone deficiency, and once-daily subcutaneous 30 mcg/kg at bedtime raised height velocity over 12 months in some prepubertal children with idiopathic deficiency. Intravenous single doses and repeated once-daily subcutaneous doses were well tolerated; transient facial flushing and pain at the injection site were the most commonly reported adverse events.

  7. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 mg Base/Vial and 1.0 mg Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 mg Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

    US Food and Drug Administration · 2013federalregister.gov

    FDA's regulatory record for sermorelin. GEREF injection 0.5 and 1.0 mg base/vial is NDA 20-443, held by EMD Serono and initially approved on September 26, 1997, indicated for the treatment of idiopathic growth hormone deficiency in children with growth failure; GEREF injection 0.05 mg base/amp is NDA 19-863, initially approved December 28, 1990, indicated for evaluating the ability of the pituitary somatotroph to secrete growth hormone. EMD Serono notified FDA in letters dated July 11 and December 2, 2008 that the products were being discontinued and requested withdrawal of the applications; approval of both NDAs was withdrawn effective June 18, 2009. FDA determined that neither product was withdrawn from sale for reasons of safety or effectiveness.

  8. The Safety and Efficacy of Growth Hormone Secretagogues

    Sigalos JT, Pastuszak AW · 2018PubMed

    Review of clinical studies of growth hormone secretagogues in humans. Secretagogues promote pulsatile release of GH that remains subject to negative feedback and can prevent supra-therapeutic GH levels and their sequelae, in contrast to exogenous GH whose drawbacks are believed to be due in part to impaired regulatory feedback. Across the available studies secretagogues improved growth velocity in children, stimulated appetite, improved lean mass in wasting states and in obese individuals, increased fat-free mass and improved sleep, and were well tolerated, with some concern for increases in blood glucose from decreased insulin sensitivity. The authors note that few long-term, rigorously controlled studies exist.

  9. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men

    Iranmanesh A, Lizarralde G, Veldhuis JD · 1991PubMed

    Twenty-one healthy men aged 21-71 of near-normal body weight were sampled every 10 minutes for 24 hours and analysed by deconvolution. At a normal body mass index, each decade of increasing age attenuated the GH production rate by 14% and the GH half-life by 6%; age and body mass index together accounted for more than 60% of the variability in 24-hour GH production rates.

  10. Interrelations between sleep and the somatotropic axis

    Van Cauter E, Plat L, Copinschi G · 1998PubMed

    In normal young adults a major GH secretory episode occurs shortly after sleep onset, in temporal association with the first period of slow-wave sleep; in men approximately 70% of daily GH output occurs during early sleep. The sleep-onset GH pulse is caused by a surge of hypothalamic GHRH release coinciding with a circadian period of relative somatostatin disinhibition, and there is a linear relationship between the amount of slow-wave sleep and the amount of concomitant GH secretion. GHRH itself promotes NREM and slow-wave sleep through central mechanisms. During ageing, slow-wave sleep and GH secretion decline with the same chronology.

  11. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone

    Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO · 1990PubMed

    Eighteen normal men received GH-releasing peptide (GHRP-6) alone and combined with GHRH. Submaximal GHRP doses plus 1 mcg/kg GHRH stimulated GH release synergistically, which the authors take as evidence that GHRP and GHRH act independently through separate mechanisms. Mild facial flushing lasting 1 to 3 minutes occurred in 16 of the 18 subjects who received GHRH.

  12. Acute hyperglycemia and activation of the beta-adrenergic system exhibit synergistic inhibitory actions on growth hormone (GH) releasing hormone-induced GH release

    Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Park S · 2003PubMed

    In healthy subjects given a 100 g oral glucose load 30 minutes before an intravenous GHRH bolus, pretreatment with glucose significantly suppressed GHRH-induced GH secretion. Acute hyperglycaemia stimulates hypothalamic somatostatin release, which in turn suppresses GH secretion from the anterior pituitary; the suppression was independent of beta-adrenergic tone.

  13. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

    Walker RF · 2006NCBI

    Editorial contrasting sermorelin with recombinant human GH in age-management practice. Because rhGH is given as a subcutaneous bolus, the amount entering the circulation is not controlled by normal feedback mechanisms, so tissue exposure to elevated concentrations is persistent and may eventually lead to tachyphylaxis and reduced efficacy. Sermorelin instead stimulates the patient's own pituitary by binding specific receptors to increase production and secretion of endogenous GH. The molecule was marketed for years for children with growth retardation but could not compete with rhGH and was withdrawn as a therapeutic entity by the manufacturer; off-label prescribing of sermorelin is not prohibited by federal law.

  14. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors

    Cunha SR, Mayo KE · 2002PubMed

    GHRH stimulates GH secretion from somatotroph cells of the anterior pituitary via a pathway in which the GHRH receptor activates adenylyl cyclase and increases cAMP production. GH secretagogues bind a distinct G protein-coupled receptor that activates phospholipase C and raises calcium and diacylglycerol rather than cAMP; co-activation of the two receptors roughly doubled the cAMP response to GHRH alone.

  15. Familial Growth Hormone Deficiency and Mutations in the GHRH Receptor Gene

    Alba M, Salvatori R · 2004PubMed

    GHRH is necessary for the proliferation of the somatotropic cells of the anterior pituitary and for the synthesis and secretion of GH. It is released by the hypothalamus into the portal hypophysial circulation and binds a membrane surface receptor, the GHRH receptor, expressed by the somatotropic cells; inactivating mutations of that receptor are a relatively common cause of inherited isolated GH deficiency.

  16. GEREF (sermorelin acetate) — Adverse Reactions, US prescribing information (FDA revision 10/2/2001), reproduced by RxList

    Serono Laboratories / RxList (WebMD) · 2001rxlist.com

    Repeated subcutaneous treatment: the most common treatment-related adverse event, in about 1 patient in 6, is a local injection reaction of pain, swelling or redness. Other treatment-related events occurred individually at under 1% — headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria. Intravenous diagnostic use: flushing of the face, injection site pain, redness and/or swelling, nausea, headache, vomiting, dysgeusia, pallor and tightness in the chest. A large proportion of patients develop anti-GRF antibodies at least once during treatment. GEREF was discontinued in the US in 2008 and FDA no longer hosts the label for either NDA 19-863 or NDA 20-443; this is a publisher's reproduction of it, not an FDA-hosted document.

Head to head

Sermorelin compared

Studied for

Conditions Sermorelin has been researched in

Want the full picture?

The complete Sermorelin research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.